The Food and Drug Administration (FDA) drug label for irinotecan includes therapeutic recommendations for UGT1A1*28 homozygous patients to reduce the risk of developing neutropenia [Irinotecan (CAMPTOSAR) drug label. Here, UGT1A1 is linked to Decreased total neutrophil count.